Intellectual property protection: impact on public health.
- Published in:
- 2005
- Publication type:
- Journal Article
Works matching IS 10109609 AND DT 2005 AND VI 19 AND IP 3
Results: 35
1
2
Highlights of the 14th model list of essential medicines.
- Published in:
- 2005
- Publication type:
- Journal Article
3
International Pharmacopoeia: fourth edition in development.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 242
- Publication type:
- Article
4
Access to Medicines: Intellectual property protection: impact on public health.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 236
- Publication type:
- Article
5
WHO Model List of Essential Medicines.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 222
- Publication type:
- Article
6
Mifepristone with misoprostol.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 220
- Publication type:
- Article
7
Methadone and buprenorphine.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 220
- Publication type:
- Article
8
Highlights of the 14th Model List of Essential Medicines.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 220
- Publication type:
- Article
9
Tigecycline: first-in-class antibiotic approved.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 219
- Publication type:
- Article
10
European marketing authorizations.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 218
- Publication type:
- Article
11
Caution on self medication.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 218
- Publication type:
- Article
12
Deregistration of thioridazine.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 217
- Publication type:
- Article
13
New drug safety initiative.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 217
- Publication type:
- Article
14
Hydromorphone extended release suspended.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 217
- Publication type:
- Article
15
Regulatory guidelines for complementary medicines.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 216
- Publication type:
- Article
16
National policy on regulation of herbal medicines.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 216
- Publication type:
- Article
17
Ayurvedic medicines and heavy metals.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 215
- Publication type:
- Article
18
Monograph for cultivation of herbal antimalarial: Artemisla annua.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 215
- Publication type:
- Article
19
Antiretrovirals: HIV, hepatic impairment and HBV/HCV.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 214
- Publication type:
- Article
20
Efalizumab: warning of thrombocytopenia.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 214
- Publication type:
- Article
21
New requirements for pseudoephedrine products.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 213
- Publication type:
- Article
22
Icodextrin peritoneal dialysis solution: falsely elevated blood glucose readings.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 213
- Publication type:
- Article
23
Pathological gambling with cabergoline.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 212
- Publication type:
- Article
24
Ezetimibe and muscle disorders.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 212
- Publication type:
- Article
25
Suicidality with SSRIs in adults.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 211
- Publication type:
- Article
26
Mifepristone: revised safety information.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 211
- Publication type:
- Article
27
Mifepristone, sepsis and blood infection.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 211
- Publication type:
- Article
28
Nesiritide: safety report and measures.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 210
- Publication type:
- Article
29
Sildenafil, tadalafil and vardenafil: eye problems reported.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 209
- Publication type:
- Article
30
Stringent conditions for COX-2 Inhibitors.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 209
- Publication type:
- Article
31
Ibuprofen: Stevens-Johnson syndrome.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 208
- Publication type:
- Article
32
Rosiglitazone: decreased high-density lipoprotein cholesterol.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 208
- Publication type:
- Article
33
Safety of fentanyl transdermal patches.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 207
- Publication type:
- Article
34
Transdermal fentanyl: abuse by adolescents.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 207
- Publication type:
- Article
35
Unfinished business: clinical pharmacology and world health.
- Published in:
- WHO Drug Information, 2005, v. 19, n. 3, p. 201
- By:
- Publication type:
- Article